Related Experiment Videos

Inhibition of (interstitial) P2Y6 receptors attenuates fibrosis progression

Lena Marie Süß1, Anna Petzendorfer1, Minh Linh Tran1

  • 1Medical Cell Biology, University of Regensburg, Universitätsstraβe 31, D-93053, Regensburg, Germany.

Insights

Extracellular nucleotide P2Y6 receptor signaling drives kidney fibrosis by activating interstitial fibroblasts. Inhibiting this pathway may offer a novel therapeutic strategy for chronic kidney disease (CKD).

Area of Science:

  • Nephrology
  • Cell Biology
  • Pharmacology

Background:

  • Chronic kidney disease (CKD) involves progressive renal fibrosis.
  • Activated interstitial fibroblasts drive fibrosis in CKD.
  • The role of extracellular nucleotide and P2 receptor signaling in fibroblast activation is unclear.

Purpose of the Study:

  • Investigate Gq/11-coupled P2Y receptor expression and function in renal interstitial fibroblasts.
  • Determine the involvement of these receptors in experimental kidney fibrosis.

Main Methods:

  • RNA in situ hybridization to detect P2Y1 and P2Y6 receptor expression.
  • Functional assays measuring intracellular Ca2+ elevation and fibroblast migration.
  • Adenine-induced nephropathy model with P2Y6 antagonist MRS2578 treatment.

Main Results:

  • P2Y1 and P2Y6 receptors expressed in renal interstitial fibroblasts.
  • P2Y6 expression significantly upregulated in experimental renal fibrosis models.
  • P2Y6 activation increased fibroblast migration.
  • P2Y6 inhibition reduced myofibroblast markers (α-smooth muscle actin, collagen I).

Conclusions:

  • Upregulated P2Y6 receptor signaling promotes myofibroblast differentiation and renal fibrosis.
  • P2Y6 signaling modulation of fibroblast migration is a key mechanism.
  • P2Y6 inhibition presents a potential therapeutic strategy for reducing renal fibrosis.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...